Sriussadaporn Sutin, Pumchumpol Wanwaroon, Lertwattanarak Raweewan, Kunavisarut Tada
Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Int J Endocrinol. 2017;2017:2619695. doi: 10.1155/2017/2619695. Epub 2017 Dec 18.
Previous studies used unequal or high daily dosages of methimazole (MMI) to compare the efficacy of once daily dose regimen (OD-MMI) with that of divided daily doses regimen (DD-MMI) in inducing euthyroidism.
To compare the efficacy of OD-MMI to that of DD-MMI using low daily dosage of MMI in inducing euthyroidism.
Fifty patients with clinically nonsevere Graves' hyperthyroidism were randomized to be treated with 15 mg/day OD-MMI or 15 mg/day DD-MMI.
21 cases (84%) in OD-MMI and 23 cases (92%) in DD-MMI were eligible for analyses. During the treatment, there was no difference in baseline characteristics, serum FT3 and FT4 reductions, and cumulative rate of achieving euthyroidism (4.8% versus 4.3%, 28.6% versus 34.8%, 71.4% versus 82.6%, and 85.7% versus 87.0% at 2, 4, 8, and 12 weeks, resp.) between both regimens. Hypothyroidism developed in DD-MMI significantly more than in OD-MMI (17.4% versus 0%, < 0.05).
Treatment with MMI at a low daily dosage of 15 mg/day OD-MMI is as effective as DD-MMI in the reduction of serum thyroid hormone levels and induction of euthyroidism. The OD-MMI regimen is preferable to the DD-MMI regimen in the treatment of clinically nonsevere Graves' hyperthyroidism. This trial is registered with Thai Clinical Trials Registry: TCTR20170529001.
既往研究使用不等量或高剂量的甲巯咪唑(MMI)来比较每日一次剂量方案(OD-MMI)与每日分次剂量方案(DD-MMI)在诱导甲状腺功能正常方面的疗效。
使用低剂量的MMI比较OD-MMI与DD-MMI在诱导甲状腺功能正常方面的疗效。
50例临床症状不严重的格雷夫斯甲亢患者被随机分为接受15mg/天的OD-MMI治疗或15mg/天的DD-MMI治疗。
OD-MMI组21例(84%)和DD-MMI组23例(92%)符合分析条件。治疗期间,两组在基线特征、血清FT3和FT4降低情况以及实现甲状腺功能正常的累积率(分别在2、4、8和12周时为4.8%对4.3%、28.6%对34.8%、71.4%对82.6%以及85.7%对87.0%)方面无差异。DD-MMI组发生甲状腺功能减退的情况显著多于OD-MMI组(17.4%对0%,P<0.05)。
每日低剂量15mg/天的OD-MMI治疗MMI在降低血清甲状腺激素水平和诱导甲状腺功能正常方面与DD-MMI同样有效。在治疗临床症状不严重的格雷夫斯甲亢时,OD-MMI方案优于DD-MMI方案。本试验已在泰国临床试验注册中心注册:TCTR20170529001。